Skip to main content

Table 3 Rectal carriage of (non-intrinsic) antibiotic resistant microorganisms

From: Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: results of a multicenter randomized placebo-controlled clinical trial

 Patients, n/N (%) 
OAPPlaceboP value
Baseline
 Number of valid rectal cultures35/39 (89.7)31/39 (79.5) 
Rectal carriage of HRE
 ESBL-E2/35 (5.7)1/31 (3.2)1.000
 Carbapenem-resistant Gram-negative bacteria1/35 (2.9)2/31 (6.5)0.597
 Carbapenemase-gene present1/35 (2.9)2/31 (6.5)0.597
 Tobramycin-resistant Gram-negative bacteria12/35 (34.3)14/31 (45.2)0.452
 Acquired aminoglycoside resistance gene present1/35 (2.8)5/31 (16.1)0.088
 Colistin-resistant Gram-negative bacteria7/35 (20.0)6/31 (19.4)1.000
 Acquired colistin resistance gene present0/35 (0.0)0/31 (0/0)0
30 days after surgery
 Number of valid rectal cultures34/36 (94.4)28/35 (80.0) 
Rectal carriage of HRE
 ESBL-E1/34 (2.9)1/28 (3.6)1.000
 Carbapenem-resistant Gram-negative bacteria0/34 (0.0)1/28 (3.6)0.452
 Carbapenemase gene present0/34 (0.0)1/28 (3.6)0.452
 Tobramycin-resistant Gram-negative bacteria15/34 (44.1)10/28 (35.7)0.606
 Acquired aminoglycoside resistance gene present7/34 (2.1)5/28 (17.9)0.318
 Colistin-resistant Gram-negative bacteria4/34 (11.9)4/28 (14.3)0.320
 Acquired colistin resistance gene present0/34 (0.0)0/28 (0.0)1.000
  1. Data are presented as n/N (%). P values are estimated using Fisher’s exact test. ESBL-E, Extended-Spectrum Beta Lactamase-producing Enterobacteriaceae; OAP, oral antibiotic prophylaxis